Basit öğe kaydını göster

dc.contributor.authorAltay, Hakan
dc.contributor.authorCavusoglu, Yuksel
dc.contributor.authorCetiner, Mustafa
dc.contributor.authorGuvenc, Tolga Sinan
dc.contributor.authorTemizhan, Ahmet
dc.contributor.authorUral, Dilek
dc.contributor.authorYesibursa, Dilek
dc.contributor.authorYildirim, Nesligul
dc.contributor.authorYilmaz, Mehmet Birhan
dc.date.accessioned2019-06-12T19:06:49Z
dc.date.available2019-06-12T19:06:49Z
dc.date.issued2017
dc.identifier.issn1016-5169
dc.identifier.urihttp://archivestsc.com/jvi.aspx?un=TKDA-79584
dc.identifier.urihttp://hdl.handle.net/11727/3476
dc.description.abstractHeart failure is an important community health problem. Prevalence and incidence of heart failure have continued to rise over the years. Despite recent advances in heart failure therapy, prognosis is still poor, rehospitalization rate is very high, and quality of life is worse. Co-morbidities in heart failure have negative impact on clinical course of the disease, further impair prognosis, and add difficulties to treatment of clinical picture. Therefore, successful management of co-morbidities is strongly recommended in addition to conventional therapy for heart failure. One of the most common co-morbidities in heart failure is presence of iron deficiency and anemia. Current evidence suggests that iron deficiency and anemia are more prevalent in patients with heart failure and reduced ejection fraction, as well as those with heart failure and preserved ejection fraction. Moreover, iron deficiency and anemia are referred to as independent predictors for poor prognosis in heart failure. There is strong relationship between iron deficiency or anemia and severity of clinical status of heart failure. Over the last two decades, many clinical investigations have been conducted on clinical effectiveness of treatment of iron deficiency or anemia with oral iron, intravenous iron, and erythropoietin therapies. Studies with oral iron and erythropoietin therapies did not provide any clinical benefit and, in fact, these therapies have been shown to be associated with increase in adverse clinical outcomes. However, clinical trials in patients with iron deficiency in the presence or absence of anemia have demonstrated considerable clinical benefits of intravenous iron therapy, and based on these positive outcomes, iron deficiency has become target of therapy in management of heart failure. The present report assesses current approaches to iron deficiency and anemia in heart failure in light of recent evidence.en_US
dc.language.isoturen_US
dc.relation.isversionof10.5543/tkda.2017.79584en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnemiaen_US
dc.subjectIron deficiencyen_US
dc.subjectHeart failureen_US
dc.titleIron deficiency and anemia in heart failureen_US
dc.typereviewen_US
dc.relation.journalTURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGYen_US
dc.identifier.volume45en_US
dc.identifier.startpage1en_US
dc.identifier.endpage38en_US
dc.identifier.wos000404230400002en_US
dc.identifier.scopus2-s2.0-85028683317en_US
dc.contributor.pubmedID28446734en_US
dc.contributor.researcherIDAAE-1392-2021en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster